Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Tislelizumab After Chemotherapy in dMMR/MSI-H or POLE/POLD1 Mutated Gastric/Colorectal Cancer
NCT06118658Phase 2Not yet recruiting
- Sponsor
- China Medical University
- Start
- Nov 2023
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in gastric adenocarcinoma, colorectal adenocarcinoma, sponsored by China Medical University. Planned start Nov 2023; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
gastric adenocarcinomacolorectal adenocarcinoma
Beyond the preview
Go deeper on NCT06118658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06118658.